Interesting. Thanks DD. I tend to think this is probably something they don't need to worry about. But, I guess one should consider that a safety issue that's not "statistically relevant" for a drug when tested alone with SoC could possibly turn into something that is an issue when combined with other HCV DAAs. Perhaps this is something to keep an eye on for TMC435.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.